With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

Multi‐omics usually refers to the crossover application of multiple high‐throughput screening
technologies represented by genomics, transcriptomics, single‐cell transcriptomics …

Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion
of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular …

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Background Patients with relapsed or refractory acute myeloid leukemia (AML) with
mutations in the FMS-like tyrosine kinase 3 gene (FLT3) infrequently have a response to …

PURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy
for relapsed/refractory FLT3-mutated (FLT3 mut) acute myeloid leukemia (AML) but seldom …

Here, we review single-cell sequencing techniques for individual and multiomics profiling in
single cells. We mainly describe single-cell genomic, epigenomic, and transcriptomic …

Advances in molecular biology, microfluidics and bioinformatics have empowered the study
of thousands or even millions of individual cells from malignant tumours at the single-cell …

Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection.
Precise characterization of clonal architecture is essential to understand the evolutionary …

Despite high initial response rates, acute myeloid leukemia (AML) treated with the BCL-2–
selective inhibitor venetoclax (VEN) alone or in combinations commonly acquires …